Data from a survey conducted by National Psoriasis Foundation is presented at 42nd annual Fall Clinical Dermatology Conference.- Novan Inc., EPI Health, a Novan company, and MC2 Therapeutics.
Novan, Inc., EPI Health, a Novan Company, and MC2 Therapeutics announced that data from a 17-question survey sponsored by the Company was published in a poster entitled, “Improving Patient Acceptability and Adherence in Psoriasis Treatment,” at the 42nd Annual Fall Clinical Dermatology Conference® taking place October 20-23, 2022, in Las Vegas, NV.
“Topical medications continue to be a mainstay of psoriasis treatment and results from this survey provide valuable insights into what attributes patients value in these medications. This is important because treatment experience impacts patient satisfaction, adherence and ultimately, outcomes,” commented Steven R. Feldman, M.D., Ph.D., Professor of Dermatology, Wake Forest University School of Medicine.
Nearly 80% of participants said they would have to notice an improvement in their symptoms in two weeks or less before discontinuing a topical treatment. In addition, 75% of patients stated they would only persevere for a week if they did not like a formulation that was prescribed for them.
The formulation attributes rated most important by those surveyed were application feel (55.2%), non-staining (49.9%), quick absorption (46.7%), non-sticky texture (39.7%), ease of application (28.5%), no unpleasant smell (22.4%) and non-greasy (16.8%). When asked about formulations they had used previously the most preferred were water-based cream (76%), oil-based foam (70%) and gel (48%).
“Patients expect to see rapid improvement of their symptoms, or they report they will discontinue treatment. They also want to have formulations that feel nice, absorb quickly and are non-staining, characteristics which affect their willingness to use and may be an important factor in treatment planning,” concluded Dr. Feldman.
EPI Health, a Novan company, and MC2 Therapeutics jointly market MC2 Therapeutics’ WSynzora (calcipotriene and betamethasone dipropionate) Cream in the US, a once-daily aqueous cream that combines the benefits of a high potency steroid plus Vitamin D for the treatment of plaque psoriasis. Wynzora Cream demonstrates a rapid onset of action with results seen in efficacy, scale and itch as early as 1 week and continued improvement at 8 weeks.
910 mins
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.